Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. (Q35749783)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15094159%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

review article

1 reference

title

Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15094159%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15094159%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Rob C Hoeben

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15094159%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

author name string

Frederik H E Schagen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15094159%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Martine Ossevoort

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15094159%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

publication date

1 April 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15094159%20AND%20SRC:MED&resulttype=core&format=json

Critical Reviews in Oncology Hematology

27 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15094159%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15094159%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15094159%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

51-70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15094159%20AND%20SRC:MED&resulttype=core&format=json

Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a.

27 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Mechanism of recovery from acute virus infection. VIII. Treatment of lymphocytic choriomeningitis virus-infected mice with anti-interferon-gamma monoclonal antibody blocks generation of virus-specific cytotoxic T lymphocytes and virus elimination

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Lymphocyte responses and cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Heterogeneity of helper/inducer T lymphocytes. II. Effects of interleukin 4- and interleukin 2-producing T cell clones on resting B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Lymphokine control of in vivo immunoglobulin isotype selection.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

The influence of IL12 on the development of Th1 and Th2 cells and its adjuvant effect for humoral immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Immune responses to adenovirus and adeno-associated virus in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Immunologic barriers to hepatic adenoviral gene therapy for transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

"Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Strategies to adapt adenoviral vectors for targeted delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Role of early region 3 (E3) in pathogenesis of adenovirus disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Immune evasion by adenoviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Tumor necrosis factor alpha induces the adenovirus early 3 promoter by activation of NF-kappaB.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Gene Therapy for Hemophilia B: Host Immunosuppression Prolongs the Therapeutic Effect of Adenovirus-Mediated Factor IX Expression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Immunomodulation with FK506 around the time of intravenous re-administration of an adenoviral vector facilitates gene transfer into primed rat liver

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic [mdx] mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Anti-T cell receptor monoclonal antibody prolongs transgene expression following adenovirus-mediated in vivo gene transfer to mouse synovium.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Immunomodulation and adenoviral gene transfer to the lungs of nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Partial correction of murine hemophilia A with neo-antigenic murine factor VIII.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Persistent and secondary adenovirus-mediated hepatic gene expression using adenovirus vector containing CTLA4IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Constitutive expression of murine CTLA4Ig from a recombinant adenovirus vector results in prolonged transgene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Effects of macrophage depletion and anti-CD40 ligand on transgene expression and redosing with recombinant adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Gene transfer to the thymus. A means of abrogating the immune response to recombinant adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Adenovirus infections in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Disseminated adenovirus disease in immunocompromised and immunocompetent children

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Characterization of an adenovirus gene transfer vector containing an E4 deletion

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

A new vector system with inducible E2a cell line for production of higher titer and safer adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Adenovirus early region 4 is required for efficient virus particle assembly

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Transfer of the CFTR Gene to the Lung of Nonhuman Primates with E1-Deleted, E2a-Defective Recombinant Adenoviruses: A Preclinical Toxicology Study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Regulation of early adenovirus transcription: a protein product of early region 2 specifically represses region 4 transcription

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Effect of the E4 region on the persistence of transgene expression from adenovirus vectors.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Expanded-capacity adenoviral vectors--the helper-dependent vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Optimization of the helper-dependent adenovirus system for production and potency in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Persistence in muscle of an adenoviral vector that lacks all viral genes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Lung-specific expression of adenovirus E3-14.7K in transgenic mice attenuates adenoviral vector-mediated lung inflammation and enhances transgene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Retention of adenovirus E19 glycoprotein in the endoplasmic reticulum is essential to its ability to block antigen presentation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

"E3/19K" protein of adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Expression of gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

1 reference

7 January 2021

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Expression of the adenovirus receptor and its interaction with the fiber knob

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Persistence of Replication-Deficient Adenovirus-Mediated Gene Transfer in Lungs of Immune-Deficient (nu/nu) Mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Viruses use stealth technology to escape from the host immune system

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Viral strategies of immune evasion

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Viral interference with antigen presentation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Creation of immune 'stealth' genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Antigenic homogeneity of adenovirus types 1, 2, 5, and 6.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Intratracheal Gene Delivery with Adenoviral Vector Induces Elevated Systemic IgG and Mucosal IgA Antibodies to Adenovirus andβ-Galactosidase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Antipeptide antisera define neutralizing epitopes on the adenovirus hexon

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Circumvention of immunity to the adenovirus major coat protein hexon.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Molecular epidemiology of adenovirus type 35 infections in immunocompromised hosts

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Genetic heterogeneity in response to adenovirus gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Adenovirus vectors as recombinant viral vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

Development of a preventive vaccine for Ebola virus infection in primates

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900172-0

7 January 2021

10.1016/S1040-8428(03)00172-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15094159%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference